Abbott Laboratories ABT reported solid second-quarter performance that underscored the strength of its presence in emerging markets, where robust growth continues. While second-quarter results have not spurred a change in projections for the rest of this year or 2014, we may see $40 per share, which was primarily driven by a lower cost of equity…